Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense June 8, 2021 Auto Bot alzheimer's disease, Biogen Inc, Clinical Trials, Health Insurance and Managed Care 0 Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.